Boston Scientific has received Food and Drug Administration approval for its spinal cord stimulation device in painful diabetic peripheral neuropathy (PDN).

The expanded indication positions Boston Scientific to challenge Abbott, Medtronic and Nevro for the emerging opportunity. Nevro, the first to market in PDN, forecast the indication could be worth up to $5 billion ahead of the approval of its device in 2021.

Boston Scientific, which competes with the same companies in the broader spinal cord stimulation market, expects its technology for providing fast-acting, paresthesia-free pain relief to be a differentiating feature of its WaveWriter Alpha device.